섬유근육통 치료제 시장 규모, 점유율, 성장 분석 : 약제 클래스별, 진단 방법별, 투여 경로별, 약제 유형별, 치료 채널별, 유통 채널별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Fibromyalgia Treatment Market Size, Share, and Growth Analysis, By Drug Class, By Diagnosis Method, By Route of Administration, By Drug Type, By Treatment Channel, By Distribution Channel, By End User, By Region - Industry Forecast 2025-2032
상품코드:1687590
리서치사:SkyQuest
발행일:2025년 03월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 섬유근육통 치료제 시장 규모는 2023년에 35억 달러로 평가되며, 예측 기간(2025-2032년)의 CAGR은 8.2%로, 2024년 37억 9,000만 달러에서 2032년에는 71억 1,000만 달러로 성장할 전망입니다.
섬유근육통은 전 세계 성인의 약 2%가 앓고 있는 만성 통증 질환으로 광범위한 통증, 피로, 수면장애 및 인지장애와 같은 부가적인 증상을 통해 나타나며, 여성의 유병률이 현저하게 높은 질환입니다. 치료법은 없지만, 증상 관리를 개선하고 환자의 삶의 질을 향상시키기 위한 다양한 치료 전략이 존재합니다. 이러한 치료 전략은 약수처리, 생활습관 개선, 비약물 요법을 통합하여 통증 완화, 수면의 질 개선, 인지 기능 문제를 해결하는 것을 목표로 합니다. 섬유근육통은 복잡하므로 다학제적 치료 접근이 필요하며, 종종 개개인의 고유한 필요에 따라 맞춤화된 맞춤형 치료의 중요성이 강조되어 이 다면적인 병태를 효과적으로 관리하기 위한 맞춤형 치료의 중요성이 강조됩니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
사례 연구
규제 상황
섬유근육통 치료제 시장 규모 : 약제 클래스별 & CAGR(2025-2032)
시장 개요
항우울제
항간질약
근이완제
기타
섬유근육통 치료제 시장 규모 : 진단 방법별 & CAGR(2025-2032)
시장 개요
혈액검사
신체검사
섬유근육통 치료제 시장 규모 : 투여 경로별 & CAGR(2025-2032)
시장 개요
경구
주사 가능
국소
섬유근육통 치료제 시장 규모 : 약제 유형별 & CAGR(2025-2032)
시장 개요
브랜드
제네릭
섬유근육통 치료제 시장 규모 : 치료 채널별 & CAGR(2025-2032)
시장 개요
병원
클리닉
홈케어
섬유근육통 치료제 시장 규모 : 유통 채널별 & CAGR(2025-2032)
시장 개요
병원 약국
소매 약국
온라인 약국
섬유근육통 치료제 시장 규모 : 최종사용자별 & CAGR(2025-2032)
시장 개요
성인
소아
섬유근육통 치료제 시장 규모 : 지역별 & CAGR(2025-2032)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
기업의 상세
제품 포트폴리오 분석
기업의 부문별 점유율 분석
매출의 전년대비 비교(2022-2024)
주요 기업 개요
Pfizer Inc.(USA)
AbbVie Inc.(USA)
Eli Lilly and Company(USA)
F. Hoffmann-La Roche Ltd.(Switzerland)
GlaxoSmithKline plc(UK)
Aptinyx Inc.(USA)
Tonix Pharmaceuticals Holding Corp.(USA)
Virios Therapeutics(USA)
Astellas Pharma Inc.(Japan)
Teva Pharmaceutical Industries Ltd.(Israel)
Boehringer Ingelheim GmbH(Germany)
Novartis AG(Switzerland)
Johnson & Johnson(USA)
Merck & Co., Inc.(USA)
Bristol-Myers Squibb Company(USA)
Takeda Pharmaceutical Company Limited(Japan)
Sun Pharmaceutical Industries Ltd.(India)
Mylan N.V.(USA)
Lupin Limited(India)
결론과 제안
KSA
영문 목차
영문목차
Global Fibromyalgia Treatment Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 3.79 billion in 2024 to USD 7.11 billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).
Fibromyalgia, a chronic pain disorder that affects approximately 2% of adults globally, manifests through widespread pain, fatigue, and additional symptoms like sleep disturbances and cognitive difficulties, with a notably higher prevalence in women. Although there is no cure, various treatment strategies exist to improve symptom management and enhance the quality of life for those affected. These strategies integrate medications, lifestyle changes, and non-pharmacological therapies, aiming to alleviate pain, improve sleep quality, and tackle cognitive issues. The complexity of fibromyalgia necessitates a multidisciplinary treatment approach, often customized to meet the unique needs of each individual, highlighting the importance of personalized care in effectively managing this multifaceted condition.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Fibromyalgia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Fibromyalgia Treatment Market Segments Analysis
Global Fibromyalgia Treatment Market is segmented by Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User and region. Based on Drug Class, the market is segmented into Antidepressants, Antiepileptics, Muscle Relaxants and Others. Based on Diagnosis Method, the market is segmented into Blood Tests and Physical Examination. Based on Route of Administration, the market is segmented into Oral, Injectable and Topical. Based on Drug Type, the market is segmented into Branded and Generic. Based on Treatment Channel, the market is segmented into Hospitals, Clinics and Homecare. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on End User, the market is segmented into Adults and Pediatrics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Fibromyalgia Treatment Market
The global fibromyalgia treatment market is primarily driven by the rising incidence of fibromyalgia across the globe. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) estimates that around five million adults in the United States are affected by this condition, with a staggering 80 to 90 percent of patients being women. This gender disparity highlights the significant toll fibromyalgia takes on women. As awareness surrounding the condition grows and diagnostic methods advance, more cases are being identified globally. Additionally, the limited number of specifically approved medications, currently just three, has led to increased dependence on off-label and generic treatments, further influencing market dynamics. The expiration of patent protections for Lyrica in June 2019 has also introduced generic alternatives, intensifying competition and impacting overall market growth.
Restraints in the Global Fibromyalgia Treatment Market
The Global Fibromyalgia Treatment market faces notable restraints due to the limited number of drugs specifically approved for this condition, currently standing at only three options. This scarcity leads to a greater reliance on off-label medications and generic antidepressants to manage symptoms. Moreover, the expiration of patent protection for Lyrica, a crucial medication for fibromyalgia treatment, in June 2019 has significantly impacted market revenues. The introduction of generic alternatives has intensified competition, which further constrains overall market growth. These factors collectively hinder advancements and limit treatment options available to individuals suffering from fibromyalgia worldwide.
Market Trends of the Global Fibromyalgia Treatment Market
The Global Fibromyalgia Treatment market is witnessing a notable trend toward the introduction of innovative therapies, driven by key industry players aiming to enhance their presence. The anticipated launch and approval of novel treatments, such as Galcanezumab by Eli Lilly and Company, highlights a strategic focus on expanding existing drug indications to better address the multifaceted needs of fibromyalgia patients. With Galcanezumab currently undergoing clinical trials for fibromyalgia, its upcoming results may significantly impact market dynamics. This proactive engagement in research and development underscores a growing commitment within the pharmaceutical sector to develop effective solutions, thereby contributing to robust market growth in the coming years.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Global Fibromyalgia Treatment Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Antidepressants
Antiepileptics
Muscle Relaxants
Others
Global Fibromyalgia Treatment Market Size by Diagnosis Method & CAGR (2025-2032)
Market Overview
Blood Tests
Physical Examination
Global Fibromyalgia Treatment Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Oral
Injectable
Topical
Global Fibromyalgia Treatment Market Size by Drug Type & CAGR (2025-2032)
Market Overview
Branded
Generic
Global Fibromyalgia Treatment Market Size by Treatment Channel & CAGR (2025-2032)
Market Overview
Hospitals
Clinics
Homecare
Global Fibromyalgia Treatment Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Fibromyalgia Treatment Market Size by End User & CAGR (2025-2032)
Market Overview
Adults
Pediatrics
Global Fibromyalgia Treatment Market Size & CAGR (2025-2032)
North America (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
US
Canada
Europe (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
Brazil
Rest of Latin America
Middle East & Africa (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)